SCHEMBL8268372

SCHEMBL8268372

CCOC(=O)C1CCN(c2nc(-c3ccc(-c4ccccc4CN4CCOCC4)cc3)nc3ccccc23)CC1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.68
KDM4E B2RXH2 4/20 0.68
TP53 P04637 2/20 0.68
ALDH1A1 P00352 4/20 0.55
TSHR P16473 4/20 0.55
HSD17B10 Q99714 2/20 0.55
NPSR1 Q6W5P4 2/20 0.55
HPGD P15428 1/20 0.55
CYP1A2 P05177 4/20 0.50
ALOX15 P16050 2/20 0.50
CYP2C19 P33261 2/20 0.50
PDE10A Q9Y233 1/20 0.47
MTOR P42345 2/20 0.47
PIK3CA P42336 1/20 0.47
CYP3A4 P08684 3/20 0.47
CYP2D6 P10635 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
MAPK1 P28482 3/20 0.46
USP2 O75604 2/20 0.46
CLK4 Q9HAZ1 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1084138 0.84 MAPT (0.86) MAPTKDM4ETP53ALDH1A1TSHR
SCHEMBL8268364 0.83 MAPT (0.77) MAPTKDM4ETP53ALDH1A1TSHR
SCHEMBL8268371 0.82 MAPT (0.74) MAPTKDM4ETP53ALDH1A1TSHR
SCHEMBL8268367 0.81 MAPT (1.00) MAPTKDM4ETP53ALDH1A1TSHR
SCHEMBL8270096 0.78 PDE5A (0.58) MAPTKDM4ETP53ALDH1A1TSHR
SCHEMBL1083969 0.78 MAPT (0.71) MAPTKDM4ETP53ALDH1A1TSHR
SCHEMBL1084000 0.78 MAPT (0.70) MAPTKDM4ETP53ALDH1A1TSHR
SCHEMBL8268359 0.77 PDE5A (0.66) MAPTKDM4ETP53ALDH1A1TSHR
SCHEMBL1084150 0.77 MAPT (0.75) MAPTKDM4ETP53ALDH1A1TSHR
SCHEMBL8270962 0.75 TP53 (0.64) MAPTKDM4ETP53ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2006034512-A2 PHENYL-SUBSTITUTED QUINOLINE AND QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF DIABETES BAYER PHARMACEUTICALS CORPORATION (US) 2006-03-30 WO disclosed